New Frontiers for Aspire Pharma
Dr Michael Tzimas, Chief Corporate Development Officer, Aspire Pharma Ltd
The company manufacture and supply quality branded and generic medicines not only to the UK, but also to an expanding international market. They pride themselves on providing their customers with cost-effective solutions, as well as a responsive, adaptable, and ethical service that meets the highest regulatory standards.
Aspire was founded on an entrepreneur’s vision to create an agile, entrepreneurial company that was not already represented in the UK. The founding principle was to take a medicine, a molecule or a device and enhance it. This might be an improved presentation, a more convenient dose, or a more acceptable formulation for patients, and that principle still drives what they do today.
Starting with a single drug licence in 2009, the company now has more than 250 products in 16 therapeutic fields, and over 250 employees.
Aspire’s mission is to make a difference in the lives of patients through the development and supply of innovative products and medicines throughout the world. And to create a business, which is agile to opportunity, unconstrained by market segment, and whose products make a valuable difference to patients and payors.
Mergers and Acquisitions
Aspire continues to supplement strong organic growth with acquisitions and strategic partnerships. Since being acquired in 2021 by an affiliate of H.I.G. Capital, a leading global alternative investment firm, Aspire has completed the acquisition of Morningside Pharmaceuticals, Morningside Healthcare and Morningside Healthcare India in October 2022.
In March 2024, the company acquired Cenoté Pharma, a category specialist in carnitine deficiencies that further strengthens their specialty pharma offering. Carnitine is an amino acid derivative whose insufficiency can impair the metabolism of essential tissues, such as those of the heart and muscle.
In October 2024, the company acquired all assets from Canute Pharma. The assets transfer has enhanced Aspire’s existing dermatology portfolio with the distribution rights for differentiated products in haptens (allergens) and test chambers for patch testing in the diagnosis of contact dermatitis (contact eczema). The assets also include a topical antibiotic gel for acne, as well as a number of ‘special’ products focused on meeting the needs of individual patients. This transfer brings a number of innovative products which will strengthen the company’s commitment to providing high-quality skincare solutions to patients, as well as open-up some opportunities for new areas of growth in the UK and other geographic territories.
These acquisitions are further validation of the long-term growth plan to create one of the largest and fastest growing UK-based pharma companies. It will see accelerated growth potential in its current and future product portfolio with over 125 complementary mid and late-stage programmes, in the UK and internationally.
Through their partnership principles that are key to address complex healthcare challenges, Aspire establishes transparent, honest relationships and maintain and grow these partnerships through shared knowledge and resources that accelerate progress. The alliances allow them to unlock potential and maximise the performance of every alliance business and every brand.
International Expansion
Whilst Aspire’s head office is in Petersfield in the UK, with an additional UK office in Leicester, there are three more offices in India with a rapidly growing network of affiliates around the world. The newly opened office in Dublin, Ireland, will provide the legal entity, with the similarity of systems and support of services across Europe.
The internationalisation of the company is and has been a constant since its inception 16 years ago. Aspire have understood that the access to knowledge around the world is fundamental to establish both scientific and commercial collaborations that would lead to a solid and sustainable growth.
Aspire, the Business Development Team play an important role in delivering Aspire’s ambitious growth strategy and delivering on their mission to improve healthcare globally.
The team focus their energies on forging “business to business” partnerships that capitalise on the partner's presence, expertise and existing distribution channels in their markets, which typically would be different than the markets where Aspire has a direct presence.
In addition, Aspire enter chosen markets in Europe directly, “business to customer”, which will allow the company to obtain Marketing Authorisations in the selected countries in its own name and livery and deliver products directly to wholesalers or direct to pharmacies and hospitals.
Aspire’s first chosen market in Europe is Germany. The company will bring their knowledge, entrepreneurial spirit and expertise from the UK market to replicate their success in Germany. This will include entering both the hospital and pharmacy tender sectors with supply chain distribution in place before the end of 2025. Aspire have appointed Katharina Pink as Chief Commercial Officer and Managing Director Germany, based at the company’s new office in Bad Homburg.
Dr Michael Tzimas, Chief Corporate Development Officer at Aspire said, “We have completed over 40 licensing agreements in the last 12 months alone. We will continue to expand presence in continental Europe and are actively seeking bolt-on acquisitions across the Netherlands, Spain and the Nordic region as well as partnerships with other pharma companies.”
Future Focus
The future for Aspire is of continued development of differentiated products that meet the market need in niche generic and specialty medicine; upweighting clinical development; new investment opportunities to bring products and companies into the portfolio with a synergistic fit to the Aspire values and areas of therapeutic focus; growth of our own portfolio of intellectual property; and a continued corporate focus on internationalisation of the Aspire brand.
Author Bio
Dr Michael Tzimas gained his PhD in Organic Chemistry from the University of Wales, Swansea. Dr Tzimas joined Aspire Pharma in June 2023 as Chief Corporate Development Officer and with over 30 years of pharmaceutical experience, is responsible for Business Development, Portfolio, Legal, International Sales, as well as Outcomes Research at Aspire.
